Journal
JOURNAL OF AUTOIMMUNITY
Volume 112, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jaut.2020.102504
Keywords
LAG3; Immune checkpoint molecules; Inhibitory receptors; Autoimmunity; Immunotherapy
Categories
Funding
- National Natural Science Foundation of China [81971523, 81671604, 81302554, 31530020, 2101000537]
- Beijing Nova Program [Z181100006218044]
- Beijing municipal science & technology commission [Z171100000417007]
- Fundamental Research Funds for the Central Universities: Peking University Clinical Medicine Plus X-Young Scholars Project [PKU2019LCXQ018]
- Peking University People's Hospital Research and Development Funds [RDF2019-03]
Ask authors/readers for more resources
Immune checkpoint molecules play pivotal roles in maintaining the immune homeostasis. Targeting these molecules, such as the classical Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Programmed Cell Death Protein 1 (PD1), achieves great success in treating cancers. However, not all the patients respond well. This urges the immunologists to identify novel immune checkpoint molecules. Lymphocyte activation gene-3 (LAG3; CD223) is a newly identified inhibitory receptor. It is expressed on a variety of immune cells, including CD4(+) T cells, CD8(+) T cells, Tregs, B cells, and NK cells. Its unique intracellular domains, signaling patterns as well as the striking synergy observed in its targeted therapy with anti-PD1 indicate the important role of LAG3 in maintaining immune tolerance. Currently, a variety of agents targeting LAG3 are in clinical trials, revealing great perspectives in the future immunotherapy. In this review, we briefly summarize the studies on LAG3, including its structure, isoforms, ligands, signaling, function, roles in multiple diseases, as well as the latest targeted therapeutic advances, with particular concern on the potential association of LAG3 with autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available